In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 
Faiez Zannad
Speaker
Faiez Zannad
Faiez Zannad Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

Specialities : Chronic Heart Failure , Pharmacology and Pharmacotherapy, Hypertension, Risk Factors and Prevention

MD, PhD, Cardiologist, Clinical pharmacologist. Trained at Université de Lorraine, Université of Lyon, France and Medical Research Council (Oxford, UK). Currently, Emeritus Professor of Therapeutics at Université de Lorraine, France. As a trialist, he contributed to building the evidence supporting modern HF therapy, notably with beta-blockers, RAASi and MRAs. As a clinical scientist his work focuses on fibrosis and biomarkers. He has served as Chairman of the French Society of Hypertension, of the ESC Working Group on Pharmacology and Drug Therapy. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop with meetings in Paris, Washington DC, in Asia and the Middle East. Professor Zannad published more than 750 peer-reviewed papers. He received the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the ESC-HFA and served as an Eugene Braunwald Scholar in 2019 at Harvard Medical School.

83 presentations from this speaker

Clinical value of anti-fibrotic strategies.

Event : Heart Failure 2019

  • Session : Anti-fibrotic therapies in heart failure.
  • Speaker : F Zannad (Vandoeuvre,FR)

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

Event : ESC Congress 2019

  • Session : Expanding opportunities for SGLT2i in clinical cardiology
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by PACE-CME, supported with an educational grant provided by Boehringer-Ingelheim/Lilly

Latest BAT results in heart failure: the 6-month data of BEAT-HF study

Event : ESC Congress 2019

  • Session : Could neuromodulation via the baroreflex work in heart failure after all?
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by CVRx Inc

Mineralocorticoid receptor antagonists.

Event : Heart Failure 2019

  • Session : Chronic heart failure: optimising patient management
  • Speaker : F Zannad (Vandoeuvre,FR)

Ongoing studies with SGLT2 inhibitors: how may new and emerging evidence inform future clinical practice?

Event : Heart Failure 2019

  • Session : Know it by heart – New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Panel discussion

Event : ESC Congress 2019

  • Session : Discussing the opportunities for SGLT2 in clinical cardiology
  • Speaker : F Zannad (Vandoeuvre,FR), TF Luscher (London,GB), C Wanner (Wuerzburg,DE), J Deanfield (,GB)
  • Organised by PACE-CME, supported with an educational grant provided by Boehringer-Ingelheim/Lilly

Potassium and heart failure.

Event : Webinar 2019

  • Session : HFA Webinars 2019
  • Speaker : S Anker (Berlin,DE), J Cleland (Glasgow,GB), M Lainscak (Murska Sobota,SI), F Zannad (Vandoeuvre,FR)

Questions and answers - Closing

Event : ESC Congress 2019

  • Session : New approach for worsening chronic heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

Residual risk is still a challenge in HFrEF patients in the modern era

Event : ESC Congress 2019

  • Session : New approach for worsening chronic heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

Summary - The expanding role of SGLT2i in cardiovascular risk, kidney disease and heart failure .

Event : ESC Congress 2019

  • Session : Discussing the opportunities for SGLT2 in clinical cardiology
  • Speaker : C Wanner (Wuerzburg,DE), F Zannad (Vandoeuvre,FR)
  • Organised by PACE-CME, supported with an educational grant provided by Boehringer-Ingelheim/Lilly

Summary and close - Know it by heart – New opportunities for cardiologists in the SGLT2 inhibitor era.

Event : Heart Failure 2019

  • Session : Know it by heart – New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : F Ruschitzka (Zurich,CH), F Zannad (Vandoeuvre,FR)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Welcome and introduction

Event : ESC Congress 2019

  • Session : New approach for worsening chronic heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

Welcome and introduction - Management of hyperkalaemia in patients with heart failure – Overcoming barriers to optimal renin-angiotensin-aldosterone system inhibitor therapy.

Event : Heart Failure 2019

  • Session : Management of hyperkalaemia in patients with heart failure – Overcoming barriers to optimal renin-angiotensin-aldosterone system inhibitor therapy
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by MedEd Global Solutions & University of Lorraine, supported with an educational grant from Vifor Pharma

Can heart failure medications be stopped after normalization of ejection fraction?

Event : ESC Congress 2018

  • Session : Starting is easy, stopping may not be: how long should we give cardiovascular drugs?
  • Speaker : F Zannad (Vandoeuvre,FR)

Closing remarks - New directions in the management of thrombotic risks in patients with heart failure.

Event : ESC Congress 2018

  • Session : New directions in the management of thrombotic risks in patients with heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

COMMANDER.

Event : ESC Congress 2018

  • Session : Meet the trialist - COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
  • Speaker : F Zannad (Vandoeuvre,FR)

Design and rationale of the EMPagliflozin outcome trial in patients with chronic heart failure (EMPEROR-Reduced)

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Treatment
  • Speaker : F Zannad (Vandoeuvre,FR)

Expanding evidence in heart failure patients: the COMMANDER HF trial.

Event : Heart Failure 2018

  • Session : Expanding the evidence in heart failure patients
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

Guidance from outcome trials: what are the clinical implications?

Event : Heart Failure 2018

  • Session : Contemporary management of a patient with heart failure and diabetes: implications from recent trials
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Physicians Academy for Cardiovascular Education

Heart Failure in focus: clinical implications in light of the new scientific data;

Event : ESC Congress 2018

  • Session : New directions in antithrombotic management of high risk patients
  • Speaker : F Zannad (Vandoeuvre,FR), M Cowie (London,GB)
  • Sponsored by Bayer AG

Heart failure in focus: results of COMMANDER-HF.

Event : ESC Congress 2018

  • Session : New directions in antithrombotic management of high risk patients
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

In patients with diabetes

Event : Heart Failure 2018

  • Session : Prevention of heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)

Inflammatory comorbidities drive HFpEF

Event : Heart Failure 2018

  • Session : HFpEF – Still an unsolved enigma?
  • Speaker : F Zannad (Vandoeuvre,FR)

New paradigms in vascular protection: exploring heart failure and coronary artery disease.

Event : ESC Congress 2018

  • Session : New concepts in vascular protection: exploring the role of antithrombotic therapy
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by Medscape Education, supported with an educational grant from BAYER AG

New paradigms in vascular protection: exploring heart failure and Coronary Artery Disease.

Event : ESC Congress 2018

  • Session : New concepts in vascular protection: exploring the role of antithrombotic therapy
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by Medscape Education, supported by an unrestricted grant provided by BAYER

NOACs - What does the future hold

Event : Heart Failure 2018

  • Session : Antithrombotics in heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)

Opening and remarks.

Event : Heart Failure 2018

  • Session : Expanding the evidence in heart failure patients
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

Opening remarks - New directions in the management of thrombotic risks in patients with heart failure.

Event : ESC Congress 2018

  • Session : New directions in the management of thrombotic risks in patients with heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

Rivaroxaban in heart failure and conorary artery disease: the COMMANDER-HF study.

Event : ESC Congress 2018

  • Session : New directions in the management of thrombotic risks in patients with heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer AG

What are the clinical implications for management of heart failure patients with diabetes?

Event : Heart Failure 2018

  • Session : Management of heart failure in patients with diabetes: implications from recent trials
  • Speaker : A Voors (Groningen,NL), M Cowie (London,GB), N Sattar (Glasgow,GB), F Zannad (Vandoeuvre,FR)
  • Sponsored by Physicians Academy for Cardiovascular Education

123I-iobenguane for Myocardial Imaging for Risk Evaluation (MIRE): the AdreView Myocardial Imaging for Risk Stratification (ADMIRE) Implantable Cardioverter Defibrillator (ICD) trial.

Event : Heart Failure 2017

  • Session : Updates on risk guided stratification for primary prevention of sudden cardiac death in heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by GE Healthcare

Cardiovascular risk reduction with empagliflozin: exploring the evidence from EMPA-REG OUTCOME®.

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Chair's introduction.

Event : Heart Failure 2017

  • Session : New opportunities for an old problem: lowering potassium to maximize heart failure therapy
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca

Conclusion - Sensor-based Cardiac Resynchronization Therapy (CRT) optimization: new results from the RESPOND-CRT clinical trial.

Event : EHRA 2017

  • Session : Sensor-based Cardiac Resynchronization Therapy (CRT) optimization: new results from the RESPOND-CRT clinical trial
  • Speaker : F Zannad (Vandoeuvre,FR), J Brugada Terradellas (Barcelona,ES)
  • Sponsored by LivaNova

Diagnosis and prognosis.

Event : Heart Failure 2017

  • Session : What a busy clinician should know about heart failure with preserved ejection fraction
  • Speaker : F Zannad (Vandoeuvre,FR)

Experience with empagliflozin: insights from practice.

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
  • Speaker : N Marx (Aachen,DE), D McGuire (Dallas,US), F Zannad (Vandoeuvre,FR), JA Udell (Toronto,CA)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Introduction - Sensor-based Cardiac Resynchronization Therapy (CRT) optimization: new results from the RESPOND-CRT clinical trial.

Event : EHRA 2017

  • Session : Sensor-based Cardiac Resynchronization Therapy (CRT) optimization: new results from the RESPOND-CRT clinical trial
  • Speaker : F Zannad (Vandoeuvre,FR), J Brugada Terradellas (Barcelona,ES)
  • Sponsored by LivaNova

Oral anticoagulation.

Event : Heart Failure 2017

  • Session : How to manage atrial fibrillation and low ejection fraction?
  • Speaker : F Zannad (Vandoeuvre,FR)

Panel Q&A / Discussion.

Event : Heart Failure 2017

  • Session : New opportunities for an old problem: lowering potassium to maximize heart failure therapy
  • Speaker : F Zannad (Vandoeuvre,FR), J Cleland (Glasgow,GB), P Van Der Meer (Groningen,NL)
  • Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca

Subanalyses in CRT: should they be trusted ? - PRO.

Event : EHRA 2017

  • Session : Data and evidence in ICD and CRT patients: what´s the value?
  • Speaker : F Zannad (Vandoeuvre,FR)

Summary and conclusions.

Event : Heart Failure 2017

  • Session : Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma

Summary and key learnings.

Event : Heart Failure 2017

  • Session : Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Novartis

Welcome and introduction - Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension.

Event : ESC Congress 2017

  • Session : Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension
  • Speaker : S Anker (Berlin,DE), F Zannad (Vandoeuvre,FR)
  • Organised by CharitĂ© Medical School, supported with an educational grant by CVRx

Welcome and introduction.

Event : Heart Failure 2017

  • Session : Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)
  • Speaker : JJV McMurray (Glasgow,GB), F Zannad (Vandoeuvre,FR)
  • Sponsored by Novartis

Broadening clinical experience of non-vitamin K antagonist oral anticoagulation in the cardiology setting.

Event : Heart Failure 2016

  • Session : Oral anticoagulation in patients with heart failure: today and tomorrow
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer

How to overcome the burden of common co-morbidities in heart failure.

Event : Heart Failure 2016

  • Session : Targeting cardiac and non-cardiac comorbidities in heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer

Interactive case discussion: what are the implications of new treatment options in achieving better outcomes in heart failure patients?

Event : Heart Failure 2016

  • Session : Implications of novel treatment strategies for the management of hyperkalemia in heart failure
  • Speaker : F Zannad (Vandoeuvre,FR), P Van Der Meer (Groningen,NL)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca

Introduction - Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions.

Event : ESC Congress 2016

  • Session : Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by Lorraine University / Course Director: Dr. Faiez Zannad / Supported by an unrestricted educational grant from AstraZeneca

Introduction.

Event : Heart Failure 2016

  • Session : Implications of novel treatment strategies for the management of hyperkalemia in heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca

Is it really beneficial?

Event : Heart Failure 2016

  • Session : Exercise training: for whom, when and how?
  • Speaker : F Zannad (Vandoeuvre,FR)

NOACs studied in atrial fibrillation.

Event : Heart Failure 2016

  • Session : What heart failure specialists can learn from trials in other disease areas
  • Speaker : F Zannad (Vandoeuvre,FR)

Optimising chronic heart failure treatment for patients with comorbidities.

Event : ESC Congress 2016

  • Session : Optimizing outcomes in patients with heart failure with reduced ejection fraction: evidence and clinical experience sharing
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Novartis Pharma AG

Panel discussion - Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions.

Event : ESC Congress 2016

  • Session : Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions
  • Speaker : F Zannad (Vandoeuvre,FR), S Anker (Berlin,DE), LM Ruilope (Madrid,ES), M Kosiborod (Kansas,US)
  • Organised by Lorraine University / Course Director: Dr. Faiez Zannad / Supported by an unrestricted educational grant from AstraZeneca

Panel discussion.

Event : Heart Failure 2016

  • Session : Optimizing RAAS inhibition in heart failure: novel treatment considerations for the management of hyperkalemia
  • Speaker : F Zannad (Vandoeuvre,FR), GMC Rosano (London,GB)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca

Questions & answers session.

Event : Heart Failure 2016

  • Session : Oral anticoagulation in patients with heart failure: today and tomorrow
  • Speaker : F Zannad (Vandoeuvre,FR), D van Veldhuisen (Groningen,NL)
  • Sponsored by Bayer

RAAS inhibition in heart failure: corner stone of therapy & potassium homeostasis.

Event : Heart Failure 2016

  • Session : Optimizing RAAS inhibition in heart failure: novel treatment considerations for the management of hyperkalemia
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca

Risk score for incident heart failure: a subject-level meta-analysis from the heart omics in ageing database

Event : Heart Failure 2016

  • Session : Population studies / Epidemiology
  • Speaker : F Zannad (Vandoeuvre,FR)

The treatment of patients with advanced heart failure.

Event : ESC Congress 2016

  • Session : Pharmacotherapy of heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)

Vagal nerve stimulation

Event : ESC Congress 2016

  • Session : What's new in chronic heart failure devices
  • Speaker : F Zannad (Vandoeuvre,FR)

Welcome and introduction.

Event : Heart Failure 2016

  • Session : Oral anticoagulation in patients with heart failure: today and tomorrow
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer

Autonomous nerve stimulation.

Event : Heart Failure 2015

  • Session : Novel devices in heart failure
  • Speaker : F Zannad (Vandoeuvre,FR)

Broadening clinical experience of novel oral anticoagulation in the cardiology setting.

Event : Heart Failure 2015

  • Session : Novel oral anticoagulant use in patients with heart failure: present and future perspectives
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer Healthcare

Chairperson’s welcome and introduction.

Event : Heart Failure 2015

  • Session : Novel oral anticoagulant use in patients with heart failure: present and future perspectives
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Bayer Healthcare

Conclusions and close - Management priorities and clinical outcomes in post-acute coronary syndrome (ACS) patients with type 2 diabetes (T2D).

Event : ESC Congress 2015

  • Session : Management priorities and clinical outcomes in post-acute coronary syndrome (ACS) patients with type 2 diabetes (T2D)
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Takeda Pharmaceuticals GmbH

Debate: what can we conclude about the safety profile of DPP-4 inhibitors in post-ACS T2D patients?

Event : ESC Congress 2015

  • Session : Management priorities and clinical outcomes in post-acute coronary syndrome (ACS) patients with type 2 diabetes (T2D)
  • Speaker : F Zannad (Vandoeuvre,FR), V Menon (Cleveland,US), PJ Grant (Leeds,GB)
  • Sponsored by Takeda Pharmaceuticals GmbH

Drug(s) of choice in atrial fibrillation.

Event : Heart Failure 2015

  • Session : Antithrombotics in heart failure: the controversy continues
  • Speaker : F Zannad (Vandoeuvre,FR)

Heart failure polypharmacy.

Event : ESC Congress 2015

  • Session : Important drug interactions: what the cardiologist should know
  • Speaker : F Zannad (Vandoeuvre,FR)

Panel Discussion - New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia.

Event : ESC Congress 2015

  • Session : New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia
  • Speaker : JJV McMurray (Glasgow,GB), F Zannad (Vandoeuvre,FR), I Pina (Detroit,US)
  • Sponsored by ZS Pharma, Inc.

Questions and answers - New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia.

Event : ESC Congress 2015

  • Session : New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia
  • Speaker : JJV McMurray (Glasgow,GB), F Zannad (Vandoeuvre,FR), I Pina (Detroit,US)
  • Sponsored by ZS Pharma, Inc.

Safety profile of DPP-4 inhibitors in post-ACS T2D patients.

Event : ESC Congress 2015

  • Session : Management priorities and clinical outcomes in post-acute coronary syndrome (ACS) patients with type 2 diabetes (T2D)
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Takeda Pharmaceuticals GmbH

Vagal and spinal cord denervation and renal denervation. Autonomic nervous system modulation.

Event : ESC Congress 2015

  • Session : Devices for heart failure: the pipeline
  • Speaker : F Zannad (Vandoeuvre,FR)

Welcome - Management priorities and clinical outcomes in post-acute coronary syndrome (ACS) patients with type 2 diabetes (T2D).

Event : ESC Congress 2015

  • Session : Management priorities and clinical outcomes in post-acute coronary syndrome (ACS) patients with type 2 diabetes (T2D)
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Takeda Pharmaceuticals GmbH

Why aren’t we titrating optimal RAAS inhibitor life-saving therapy?

Event : ESC Congress 2015

  • Session : New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by ZS Pharma, Inc.

Addressing the long standing burden of heart failure: is it time for alternative approaches?

Event : ESC Congress 2014

  • Session : Recent advances in our understanding of the failing heart: what have we learned, what needs to be done?
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Novartis Pharma AG

Heart failure polypharmacy.

Event : ESC Congress 2014

  • Session : Important drug interactions - what you should know!
  • Speaker : F Zannad (Vandoeuvre,FR)

New insights into preventing macrovascular disease and cardiovascular mortality.

Event : ESC Congress 2014

  • Session : The power of prevention: cardiovascular disease in type 2 diabetes
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Takeda Pharmaceuticals International

Overcoming diuretic resistance.

Event : ESC Congress 2014

  • Session : Novel clinical aspects on the cardiorenal link
  • Speaker : F Zannad (Vandoeuvre,FR)

Cardiovascular outcome trials: what can we expect to learn?

Event : ESC Congress 2013

  • Session : Time to EXAMINE new strategies for the management of acute coronary syndrome patients with type 2 diabetes?
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Takeda

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are